Aprea Therapeutics, Inc.: cashflow_financing
| Value | {"amount": 440728, "concept": "us-gaap:NetCashProvidedByUsedInFinancingActivities", "currency": "USD"} |
|---|---|
| Period | 2025-01-01 – 2025-06-30 |
| Status | current |
| Entity | Aprea Therapeutics, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:02:26.698441+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/df95ad89-f742-4775-b1ab-4b2993e16260
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001558370-25-011152Retrieved: 2026-08-19T18:02:26.698441+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001781983/cashflow-financing/2025-06-30 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/df95ad89-f742-4775-b1ab-4b2993e16260
History
- no predecessors — first report